Inovio Pharma (INO) Swings to Q3 Profit

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. MSFT
6. NVDA
7. SPY
8. SKYD
9. IBM
10. CRWV

Go back to Inovio Pharma (INO) Swings to Q3 Profit

Inovio’s INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer

November 5, 2015 8:01 AM EST

PLYMOUTH MEETING, Pa., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today an interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell responses and was well tolerated in all evaluable patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18.

The immunology results show that INO-3112 generated robust HPV16/18 specific CD8+ T cell responses and antibodies against HPV16/18 in all 10 tested patients who received all treatments. These results will be presented today and tomorrow at the 30th Anniversary Annual... More